Cabinet nod for 100-bed hospital in Delhi | WeForNews | Latest News, Blogs Cabinet nod for 100-bed hospital in Delhi – WeForNews | Latest News, Blogs
Connect with us

Health

Cabinet nod for 100-bed hospital in Delhi

Published

on

Ravishankar Prasad

New Delhi, May 2 (IANS) The Union Cabinet chaired by Prime Minister Narendra Modi on Wednesday approved the construction of a 100-bed hospital in Delhi at an estimated cost of Rs 95 crore.

Addressing the media here, Law Minister Ravi Shankar Prasad said the hospital would come up in the Najafgarh area of west Delhi. “There are about 73 villages around Najafgarh which has a population of 13.65 lakh, but there is no good hospital around.”

This hospital will have departments of medicine, gynaecology, and paediatric surgery and a blood bank, among other facilities, the minister said.

IANS

Health

Delhi hospital doctors halt OPD services to protest assault

The doctors’ associations are furious that the FIR in the case was lodged in the name of an individual rather than the institution, which allegedly goes against the directions of the Delhi and central governments.

Published

on

By

Safdarjung Hospital Delhi

New Delhi, Sep 29 : Barring emergency cases, the Resident Doctors Association (RDA) of Delhi government’s Maharishi Valmiki Hospital on Tuesday announced all essential and non-essential services provided by its members had been withdrawn to protest against an assault on a doctor.

The RDA said it protested the hospital administration’s action not to lodge an institutional FIR against a patient and her attendant for assaulting an on-duty doctor on Saturday.

The RDA formally informed the hospital Medical Superintendent about the protest through a notice.

The notice read: “Since no confirmation has been made till date, we are left with no alternative but to withdraw resident doctors from essential services from 10 a.m. today, for which intimation was given to you on September 26 and again on September 28.”

“We are disheartened by the way this issue is being handled. The doctor concerned is under severe mental stress, and things may worsen for him if he doesn’t get institutional support on priority,” it said.

“Who will be responsible if something goes wrong with the resident doctor? We don’t want the patients to suffer and want to resume duties at the earliest, but not at the cost of threat to our lives, integrity, and respect towards the profession,” the RDA warned.

Meanwhile, RDAs of various government hospitals also expressed their solidarity with the victim doctor. The RDAs of Safdarjung Hospital, Lady Hardinge Medical College, Baba Sahib Ambedkar Medical College and Hospital, and Guru Teg Bahadur Hospital extended support to the protest by the doctors and also the demand to lodge an institutional FIR in the case of assault.

“We condemn the assault, extend our deepest support and stand unanimously and in solidarity with the protesting Resident Doctors Association of Maharishi Valmiki Hospital and demand immediate appropriate action by the authorities against the accused,” the RDAs said.

The doctors’ associations are furious that the FIR in the case was lodged in the name of an individual rather than the institution, which allegedly goes against the directions of the Delhi and central governments.

On Saturday, Dr Rahul Jain was allegedly assaulted by a patient, identified as Priyanka, and her attendant Naresh when the doctor asked them to come by turn in the operation theatre. He had also asked them to wear masks.

Later, Dr Jain lodged an FIR against both at the Bawana police station under Sections 186, 188, 353, 332, 506 and 34 of the IPC and other relevant laws.

Continue Reading

Health

Serum Institute to manufacture 200mn doses of Covid-19 vaccine

As a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX‑CoV2373, Novavax’s Covid‑19 vaccine candidate
US-based Novavax’s vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirus

Published

on

Covid 19 Vaccine

New Delhi, Sep 29 : A further collaboration among the Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective Covid-19 vaccines for India and low-and middle income countries.

In August, Novavax signed a deal with Pune-based Serum Institute to produce a minimum of one billion doses of its vaccine candidate for low-and middle-income countries and India.

However, as a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate.

“Today’s agreement with Serum Institute enhances Novavax’ commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents,” said Stanley C. Erck, President and Chief Executive Officer of Novavax.

“We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks,” the company said in a statement.

US-based Novavax’s vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirus.

Serum is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses). It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by Serum are accredited by the World Health Organization, Geneva and are being used in approximately 170 countries across the globe.

Moreover, the Indian Council of Medical Research (ICMR) and SII have also partnered for clinical development of a glycoprotein subunit nanoparticle adjuvanted vaccine developed by Novavax.

The trial will be initiated in the second half of October after the vaccine is manufactured by SII. The trial is led by ICMR-National AIDS Research Institute (NARI), Pune.

Meanwhile, at a Union Health Ministry briefing on the prevailing Covid-19 situation in the country, an ICMR official said three vaccines are at the clinical trial stage in India.

“Cadila and Bharat Biotech have completed phase-I trials. Serum Institute has completed phase II-B3 trials, and will start phase-III trial (with 1,500 patients at 14 locations) after clearances,” said Balram Bhargava, DG, ICMR.

Apart from Novavax-SII trials, other drugmakers such as Pfizer Inc and Moderna Inc have already begun large late-stage studies of their experimental vaccines.

Continue Reading

Disaster

Official COVID-19 death toll probably underestimates true total – WHO

Published

on

World Health Organisation

GENEVA: The official global toll of deaths from COVID-19 probably underestimates the true total – suggesting it could be over a million already, a World Health Organization official said on Monday.

“If anything, the numbers currently reported probably represent an underestimate of those individuals who have either contracted COVID-19 or died as a cause of it,” Mike Ryan, the WHO’s top emergencies expert, told a briefing in Geneva.

“When you count anything, you can’t count it perfectly but I can assure you that the current numbers are likely an underestimate of the true toll of COVID,” he said.

Continue Reading

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.